AVANIR Pharmaceuticals (AVNR) Receives European Patent Approval for Extended Commercial Exclusivity for Zenair
AVANIR Pharmaceuticals (AVNR) acquires, develops and commercializes therapeutic products for the treatment of chronic diseases of the central nervous system, as well as inflammatory and infectious diseases. The company today announced the European patent office has granted the company a new patent, which extends the exclusivity period for its lead product candidate, Zenvia - used in the treatment of pseudobulbar affect (PBA) - through 2023. The new European patent fits well into the company’s objectives, encompassing the company's current clinical development programs in PBA and diabetic peripheral neuropathic (DPN) pain, as well as other neurologic conditions. PBA is a disinhibition…